Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2019-08-06 Regulatory Filings
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-08-06 English
10-Q
Interim / Quarterly Report Q2 2019
2019-07-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 31, 2019, reporting the company's financial and operating results for the quarter ended June 30, 2019. It includes a press release as an exhibit announcing these results. The document is relatively short (3642 characters) and primarily serves as a current report announcing quarterly financial results, not a full interim report with detailed financial statements. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly/periodical financial results with key highlights only.
2019-07-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 12, 2019, reporting the termination of a material definitive agreement between MacroGenics, Inc. and Servier. It includes a summary of the agreement and references prior filings (10-K and S-1) for full details. The document also attaches a press release about the termination. The content is an announcement of a significant corporate event (termination of an agreement) rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-07-17 English
SC 13G
Major Shareholding Notification
2019-06-27 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-05-23 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.